A. O. Sartor Et Al. , "Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.," JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Sartor, A. O. Et Al. 2011. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15 .
Sartor, A. O., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. H., Shen, L., ... De Bono, J. S.(2011). Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.
Sartor, A. Et Al. "Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.," JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Sartor, A. O. Et Al. "Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011
Sartor, A. O. Et Al. (2011) . "Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.
@article{article, author={A. O. Sartor Et Al. }, title={Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2011}